The Peptide Desk The Peptide Desk

This information is for research and educational purposes only. No medical recommendations. Products are not approved for human use. For health questions, consult a doctor.

Lexicon
Mitochondria

SR9009 (Stenabolic)

A Rev-erb agonist and exercise-mimetic candidate that increased endurance in animal models but struggles with poor bioavailability in humans.

1 min read 6 sources

To the product To the sources
White tablet bottle with a black TPD label for SR9009 on a white podium, next to it a molecule model of blue, white and greenish glass spheres in a bright lab
Preclinical · not approved

Summary

At a glance

Sources checked on 26 Oct 2026

In humans
0 trials

no registered trial, as of 26 Oct 20264

Targets
2 receptors

REV-ERBα and REV-ERBβ, switches of the internal clock2

Half-maximal inhibition at REV-ERBα
670 nM

Cell assay, 800 nM at REV-ERBβ2

Total cholesterol (mice)
-47 %

obese mice after 30 days, injected, triglycerides -12%2

  • SR9009 is a synthetic agonist at the nuclear receptors REV-ERBα and REV-ERBβ. They control the internal clock and parts of metabolism.25
  • In mice SR9009 and the related SR9011 changed the daily rhythm of behaviour and clock genes, energy expenditure rose.2
  • Obese mice lost more weight and fat with it, total cholesterol fell by 47 percent. In muscle activating REV-ERBα strengthened the mitochondria and endurance.21
  • Part of the effect does not depend on REV-ERB: in cells completely without these receptors SR9009 still changed metabolism and cell growth.3
  • In all the animal studies mentioned SR9009 was injected. There are no studies in humans. Everything here is preclinical research, not a recommendation.214
Profile

Updated May 2026

Class
Rev-erb agonist

not a SARM

Use
Oral

in mg, several times daily

Half-life
short
WADA
Banned

hormone and metabolic modulators

Sizes
10 to 20 mg

2 sizes in the shop

Contents 13 sections
  1. At a glance
  2. What is SR9009?
  3. How it works
  4. How to take it
  5. Dosing
  6. What the research shows
  7. Research status
  8. Side effects
  9. Storage
  10. Related compounds
  11. FAQ
  12. Glossary
  13. Sources

What is SR9009?

SR9009, often called Stenabolic, is an agonist at the Rev-erb receptor, a switch of the internal clock and energy metabolism. It is often mentioned alongside cardarine but is not a SARM and not a PPAR agonist. The idea: mimic part of the endurance and metabolic effects of training.

Up front: SR9009 has very poor oral bioavailability, the impressive mouse effect hardly translates 1:1 to the oral human.

Comparison

Exercise mimetics in the lexicon

Substances listed as exercise mimics in the TPD lexicon, with their target as described there. Tap a card to open its entry.

REV-ERB agonist SR9009 (Stenabolic) REV-ERB
ERR agonist SLU-PP-332 ERR PPAR-delta agonist Cardarine (GW-501516) PPARδ AMPK activator AICAR AMPK

Simplified: different switches in energy metabolism. None of them replaces training.

How it works

Through the Rev-erb receptor SR9009 influences the formation of new mitochondria and energy metabolism in muscle. In mice this markedly increased endurance performance. SR9009 does not act on the androgen receptor, so it suppresses no hormone axis.

Where it acts

Where SR9009 acted in mouse studies

Tap a point or a card. Colour = REV-ERB. All from cell and mouse studies.

  1. Brain (internal clock)

    A single dose shifted the daily rhythm of activity and clock genes in the hypothalamus2

    REV-ERB
  2. Skeletal muscle

    More mitochondria, mice ran longer and further1

    REV-ERB
  3. Fat tissue

    Less fat mass in obese mice2

    REV-ERB
  4. Liver and blood lipids

    Total cholesterol 47 percent, triglycerides 12 percent lower2

    REV-ERB

Known targets2

Compound PubChem CID 57394020 (CHEMBL1961796): two described targets, type of action on each card.

REV-ERBα
Gene
NR1D1
UniProt
P20393
ChEMBL
CHEMBL1961783
Action
Agonist in cell assays (IC50 670 nM)
REV-ERBβ
Gene
NR1D2
UniProt
Q14995
ChEMBL
CHEMBL1961784
Action
Agonist in cell assays (IC50 800 nM)
Glass muscle fibre with a row of orange glowing mitochondria, two blue molecules docking on above them
Via REV-ERBα SR9009 strengthened the mitochondria in muscle in mice. Symbolic image.

How to take it

Oral, spread over the day because of the short duration.

  • Frequently several times daily, often also before training.
  • With some water, with or without food.
A glass of water, a white tablet bottle with a black TPD label for SR9009 and a few white tablets on a white tray, light blue running shoes behind them
Sold as a tablet at TPD, injected in the studies. Symbolic image.

Dosing

Dosing

Dosing, titration and syringe

Loading the dosing information …

  • Getting started and stepping up, drawn as a staircase
  • Units on the U-100 syringe for every step
  • How long one vial lasts

What the research shows

The well-known study (Woldt, Nature Medicine 2013) showed in mice that SR9009 via Rev-erbalpha increased the oxidative capacity of muscle and raised running endurance by about 50 percent. That is impressive but animal research, often with injection. In the orally dosed human the effect is questionable because of the poor bioavailability.

Study results

What the trials measured

Interactive: switch tabs, tap points, show or hide arms. Arms are named relative to each other, no dosing advice.

Blood values after 30 days2

Change compared with mice without compound, in percent

Total cholesterol2
With SR9009 -47%
Free fatty acids2
With SR9009 -23%
Blood sugar2
With SR9009 -19%
Triglycerides2
With SR9009 -12%
Leptin2 in line with less fat
With SR9009 -80%

Obese mice on a high-fat diet, injected into the abdominal cavity twice daily for 30 days. They lost 60 percent more weight than the comparison group and had less fat mass, at the same food intake.

Half-maximal inhibition per receptor2

IC50 in nanomolar, lower means stronger

REV-ERBα2
With SR9009 670 nM
REV-ERBβ2
With SR9009 800 nM

REV-ERB represses genes, an agonist strengthens this repression. What was measured is therefore how strongly SR9009 inhibits the reading of a test gene.

Row of test tubes shading from yellow to blue, a glowing sun in the first one and a glass moon in the last
Internal clock and metabolism, so far studied only in cells and mice. Symbolic image.

Research status

Where the research stands

ClinicalTrials.gov lists no trial with SR9009. All data come from cell assays and mouse models. As of 26 Oct 2026. 4

  1. Preclinical Cell assays and mouse models on internal clock, metabolism and endurance
  2. Phase 1 no registered trial
  3. Phase 2 no registered trial
  4. Phase 3 no registered trial
  5. Approval not yet
Not approved. ChEMBL lists SR9009 without a clinical phase.4

So far there is no registered trial in humans. 4

Side effects

  • Solid human data are largely missing.
  • Few acute side effects are generally reported, but that does not hide the missing data.
  • Banned in official competition.

Storage

Store dry, cool and protected from light, out of reach of children. Keep the original container closed and mind the expiry date.

Three white tablet bottles on a bright shelf next to a folded light blue towel
Dry, cool and away from light. Symbolic image.

Related

Related compounds

A different path: all in the TPD lexicon.

SR9009 (Stenabolic)
Cardarine (GW-501516) Often named together, different nuclear receptor: PPAR-delta SLU-PP-332 Different nuclear receptor: ERR AICAR Activates the energy enzyme AMPK MOTS-c Peptide from the mitochondria, metabolism BAM15 Different path: mitochondrial uncoupler

FAQ

Common questions about SR9009 (Stenabolic)

Short answers, each backed by the sources below.

Are there studies in humans?

No. As of 26 October 2026 ClinicalTrials.gov lists no trial with SR9009. ChEMBL lists it without a clinical phase. All data come from cell assays and mouse models.46

What does SR9009 do?

It activates REV-ERBα and REV-ERBβ, two nuclear receptors of the internal clock. They repress genes, including for fat and cholesterol production. In mice even a single dose changed the daily rhythm of activity and clock genes.2

What did the endurance study show?

Muscles without REV-ERBα had fewer mitochondria and worse endurance. Mice injected with SR9009 ran longer and further in the endurance test than the comparison group. The text of the study gives no percentage for this, it is only shown as a chart.1

What happened in obese mice?

After 30 days with two injections a day they lost 60 percent more weight than the comparison group and had less fat mass, without eating less. Total cholesterol fell by 47 percent, blood sugar by 19 and triglycerides by 12 percent.2

Does SR9009 act only via REV-ERB?

Apparently not. A research group removed REV-ERBα and REV-ERBβ completely from liver and stem cells. SR9009 still reduced cell survival there, changed metabolism and gene reading. According to the authors SR9009 is therefore not a pure stand-in for REV-ERB.3

Does it work as a tablet too?

That has not been studied. In the endurance and the obesity study SR9009 was injected into the abdominal cavity. There are no data on oral absorption in humans.12

Which side effects are known?

There are no solid data because SR9009 has never been tested in humans. The mouse studies measured effects, not systematic side effects.4

Glossary

Terms explained briefly

Dotted words in the text open these explanations directly.

Agonist
A substance that activates a receptor, like a key that fits and turns the lock.
Bioavailability
Share of a substance that actually reaches the blood after intake.
Exercise mimetic
A substance that mimics parts of the effects of exercise in the body without training. So far a research term.
IC50
Concentration at which a substance inhibits a process by half. Lower means stronger.
Internal clock
Network of genes and proteins that controls sleep, hormones and metabolism in a rhythm of about 24 hours.
Mitochondria
Power plants of the cell. Inside them fat and sugar are turned into energy using oxygen.
Nuclear receptor
A receptor inside the cell that directly switches genes on or off once activated.
Preclinical
Research before first use in humans, in cell cultures and animal models. Results cannot be transferred directly to humans.
REV-ERB
Two nuclear receptors, REV-ERBα and REV-ERBβ, that repress genes in a daily rhythm as part of the internal clock.
SARM
Selective androgen receptor modulator. SR9009 is not one, it does not act on the androgen receptor.

Evidence

Sources

Show all 6 sourcesHide sources 3 Studies1 Trial registry2 Database checked 26 Oct 2026

Studies

  1. REV-ERBα controls mitochondria and endurance in muscle (mice)

    Woldt et al., Nature Medicine, 2013

    DOI 10.1038/nm.3213 PMID 23852339
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed, PMC (Volltext)
  2. Synthetic REV-ERB agonists, internal clock and metabolism (mice)

    Solt et al., Nature, 2012

    DOI 10.1038/nature11030 PMID 22460951
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed, PMC (Volltext)
  3. SR9009 also acts without REV-ERB

    Dierickx et al., Proceedings of the National Academy of Sciences, 2019

    DOI 10.1073/pnas.1904226116 PMID 31127047
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed

Trial registry

  1. Search on ClinicalTrials.gov (no trial)

    ClinicalTrials.gov, U.S. National Library of Medicine

    Checked 26 Oct 2026 via ClinicalTrials.gov API v2

Database

  1. Structure of SR9009 in PubChem

    PubChem, U.S. National Library of Medicine (CID 57394020)

    Checked 26 Oct 2026 via PubChem
  2. SR9009 in ChEMBL (no clinical phase)

    ChEMBL, EMBL-EBI (CHEMBL1961796)

    Checked 26 Oct 2026 via ChEMBL

In the shop

SR9009 (Stenabolic) in the catalog

Sizes, prices and shipping times are on the product page.

To the product